ARCT
Income statement / Annual
Last year (2023), Arcturus Therapeutics Holdings Inc.'s total revenue was $157.75 M,
a decrease of 23.33% from the previous year.
In 2023, Arcturus Therapeutics Holdings Inc.'s net income was -$29.73 M.
See Arcturus Therapeutics Holdings Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$157.75 M
|
$205.76 M
|
$12.36 M
|
$9.54 M
|
$20.79 M
|
$15.75 M
|
$13.00 M
|
$20.38 M
|
$6.14 M
|
$0.00
|
Cost of Revenue |
$2.96 M |
$143.05 M |
$171.86 M |
$55.95 M |
$32.44 M |
$16.98 M |
$410,000.00 |
$294,000.00 |
$51,000.00 |
$0.00 |
Gross Profit |
$154.79 M |
$62.70 M |
-$159.50 M |
-$46.41 M |
-$11.65 M |
-$1.23 M |
$12.59 M |
$20.09 M |
$6.09 M |
$0.00 |
Gross Profit Ratio |
0.98 |
0.3 |
-12.91 |
-4.86 |
-0.56 |
-0.08 |
0.97 |
0.99 |
0.99 |
0 |
Research and Development
Expenses |
$192.13 M
|
$147.75 M
|
$173.76 M
|
$57.85 M
|
$33.64 M
|
$16.98 M
|
$15.92 M
|
$18.39 M
|
$13.46 M
|
$25.11 M
|
General & Administrative
Expenses |
$52.87 M
|
$46.07 M
|
$41.45 M
|
$23.22 M
|
$12.66 M
|
$20.58 M
|
$7.57 M
|
$5.36 M
|
$4.99 M
|
$5.84 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$52.87 M
|
$46.07 M
|
$41.45 M
|
$23.22 M
|
$12.66 M
|
$20.58 M
|
$7.57 M
|
$5.36 M
|
$4.99 M
|
$5.84 M
|
Other Expenses |
$0.00 |
-$244,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$348,000.00 |
$1.42 M |
$1.25 M |
$2.13 M |
Operating Expenses |
$245.00 M |
$193.58 M |
$215.21 M |
$81.06 M |
$46.30 M |
$37.56 M |
$23.49 M |
$25.17 M |
$19.70 M |
$33.08 M |
Cost And Expenses |
$235.95 M |
$193.58 M |
$215.21 M |
$81.06 M |
$46.30 M |
$37.56 M |
$23.49 M |
$25.17 M |
$19.70 M |
$33.08 M |
Interest Income |
$17.36 M |
$2.58 M |
$753,000.00 |
$470,000.00 |
$408,000.00 |
$514,000.00 |
$89,000.00 |
$798,000.00 |
$338,000.00 |
$239,000.00 |
Interest Expense |
$767,000.00 |
$420,000.00 |
$2.67 M |
$361,000.00 |
$446,000.00 |
$186,000.00 |
$150,000.00 |
$295,000.00 |
$251,000.00 |
$2,000.00 |
Depreciation &
Amortization |
$2.96 M
|
$1.53 M
|
$1.19 M
|
$882,000.00
|
$684,000.00
|
$582,000.00
|
$410,000.00
|
$294,000.00
|
$51,000.00
|
$31,000.00
|
EBITDA |
-$24.17 M
|
$13.70 M
|
-$201.66 M
|
-$70.64 M
|
-$24.42 M
|
-$20.72 M
|
-$10.34 M
|
-$947,000.00
|
-$1.72 M
|
-$32.81 M
|
EBITDA Ratio |
-0.15 |
0.06 |
-16.21 |
-7.53 |
-1.23 |
-1.33 |
-0.8 |
-1.23 |
-3.2 |
0 |
Operating Income Ratio
|
-0.5
|
0.06
|
-16.41
|
-7.5
|
-1.23
|
-1.38
|
-0.81
|
-1.23
|
-3.21
|
0
|
Total Other
Income/Expenses Net |
$50.32 M
|
-$1.53 M
|
-$822,000.00
|
-$624,000.00
|
-$478,000.00
|
$26,000.00
|
-$409,000.00
|
-$536,000.00
|
$11,000.00
|
$227,000.00
|
Income Before Tax |
-$27.89 M |
$10.64 M |
-$203.67 M |
-$72.15 M |
-$25.99 M |
-$21.79 M |
-$10.90 M |
-$24.53 M |
-$19.40 M |
-$32.85 M |
Income Before Tax Ratio
|
-0.18
|
0.05
|
-16.48
|
-7.56
|
-1.25
|
-1.38
|
-0.84
|
-1.2
|
-3.16
|
0
|
Income Tax Expense |
$1.84 M |
$1.30 M |
$3.19 M |
-$784,000.00 |
-$270,000.00 |
$212,000.00 |
$1,000.00 |
$73,000.00 |
$51,000.00 |
-$17,000.00 |
Net Income |
-$29.73 M |
$9.35 M |
-$206.86 M |
-$71.36 M |
-$25.72 M |
-$21.79 M |
-$10.90 M |
-$24.60 M |
-$19.45 M |
-$32.83 M |
Net Income Ratio |
-0.19 |
0.05 |
-16.74 |
-7.48 |
-1.24 |
-1.38 |
-0.84 |
-1.21 |
-3.17 |
0 |
EPS |
-1.12 |
0.35 |
-7.86 |
-3.51 |
-2.13 |
-2.16 |
-3.53 |
-6.25 |
-6.29 |
-16.81 |
EPS Diluted |
-1.12 |
0.35 |
-7.86 |
-3.51 |
-2.13 |
-2.16 |
-3.53 |
-6.25 |
-6.29 |
-16.81 |
Weighted Average Shares
Out |
$26.63 M
|
$26.45 M
|
$26.32 M
|
$20.31 M
|
$12.07 M
|
$10.07 M
|
$3.09 M
|
$3.94 M
|
$3.09 M
|
$1.95 M
|
Weighted Average Shares
Out Diluted |
$26.63 M
|
$27.09 M
|
$26.32 M
|
$20.31 M
|
$12.07 M
|
$10.07 M
|
$3.09 M
|
$3.94 M
|
$3.09 M
|
$1.95 M
|
Link |
|
|
|
|
|
|
|
|
|
|